Together with Muscular Dystrophy Canada (MDC) we are pleased to invite you to our CPD-Accredited webinar ‘Understanding the molecular mechanisms of Myotonic dystrophy Type 1 to develop therapeutic strategies’. This webinar is primarily targeted at Canadian clinicians, academics, and trainees with an interest in neuromuscular disease.

Chair:

• Dr. Élise Duchesne | Associate Professor, Department of Health Sciences, Université du Québec à Chicoutimi Researcher, Groupe de recherche interdisciplinaire sur les maladies neuromusculaires (GRIMN)

Agenda:

Muscle stem cell defects in Myotonic Dystrophy Type 1: physiopathology and therapeutic avenues

• Dr. Nicolas Dumont | Associate professor, Rehabilitation department, University of Montreal Principal Investigator, Musculoskeletal health research axis, Sainte-Justine Hospital research center

Exercise is muscle mitochondrial medicine in DM1

• Dr. Vladimir Ljubicic | Associate Professor in the Department of Kinesiology, McMaster University, Tier 2 Canada Research Chair in Neuromuscular Plasticity in Health and Disease

Learning Objectives:

1. Myotonic dystrophy type 1 (DM1).
2. The extent of skeletal muscle impairments experienced by individuals living with DM1.
3. The fundamental molecular mechanisms that underlie this disease.
4. Present and future therapeutic avenues for addressing muscular impairments in DM1.

NMD4C and MDC are providing organizational and technical support. This is an independent clinical/academic webinar with no industry sponsorship or influence. The NMD Rounds & Educational Webinars is a self-approved group learning activity (Section 1) as defined by the Maintenance of Certification Program of the Royal College of Physicians and Surgeons of Canada.